Cagrilintide vs Semaglutide
A side-by-side research comparison of Cagrilintide and Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cagrilintide | Semaglutide |
|---|---|---|
| Full name | Cagrilintide (AM833) | Semaglutide (GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Investigational (Phase III) | FDA Approved |
| Mechanism | Acts as a dual amylin and calcitonin receptor agonist. It engages satiety centers in the area postrema and hindbrain, reducing food intake and slowing gastric emptying through a pathway distinct from GLP-1. | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. |
| Molecular weight | ~3963 Da | 4,114 Da |
| Half-life | ~7-8 days | 7 days (168 hours) |
| Bioavailability | High via subcutaneous injection | High (SubQ ~89%), Moderate (oral ~1% with SNAC) |
| Typical dose | 0.3-2.4 mg (titrated) | 0.25 mg → titrate up to 2.4 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
Cagrilintide reported benefits
- Appetite suppression and increased satiety
- Meaningful weight loss
- Complements GLP-1 agonists (additive effect)
- Slows gastric emptying
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Related comparisons
Research and educational reference only. Not medical advice.